HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Davison, S. Articles by Davis, S. Search for Related Content PubMed PubMed Citation Articles by Davison, S. Articles by Davis, S.

Pharmacokinetics and Acute Safety of Inhaled Testosterone in Postmenopausal Women

From the Jean Hailes Foundation, Clayton, Australia (Dr Davison, Ms Adams, Dr Davis); Aradigm Corp, Hayward, California (Dr Thipphawong, Dr Blanchard, Dr Liu, Mr. Morishige, Dr Gonda, Mr Okikawa, Dr Otulana); Centre for Pharmaceutical Research, University of South Australia (Dr Evans); Department of Biochemistry, Monash University, Melbourne, Australia (Dr Davison); and Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia (Dr Davis).

This was a preliminary feasibility study to assess the pharmacokinetics and acute safety of a single dose of orally inhaled testosterone via the AERx system, a novel handheld aerosol delivery system in postmenopausal women. Twelve postmenopausal women stabilized on oral estrogen therapy were treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation. Plasma concentrations of sex steroids were measured between 1 and 360 minutes. Pulmonary and cardiovascular adverse events were monitored. Inhaled testosterone produced a dose-dependent increase in plasma total and free testosterone. At the highest dose (0.3 mg), total and free testosterone increased from baseline (mean ± SD, 0.6 ± 0.3 nmol/L, 2.5 ± 1.0 pmol/L) to maximum levels of 62.6 ± 20.4 nmol/L (total) and 168.2 ± 50.2pmol/L(free), occurring 1 to 2 minutes after dosing. A 2-compartment model best described the free and total testosterone pharmacokinetic profile. Dihydrotestosterone levels were higher than baseline at 60 minutes (P < .0002). Estradiol did not vary, but sex hormone binding globulin and albumin fell. There were no adverse events related to the treatment. Administration of inhaled testosterone is safe and achieves a supraphysiologic "pulse" kinetic profile of total and free testosterone with a rapid return to pretreatment levels.

Key Words: Inhaled testosterone • AERx • drug safety • pharmacokinetics • pharmacodynamics

Address for reprints: Sonia Davison, Jean Hailes Foundation, 173 Carinish Road, Clayton, Victoria, Australia.

This article has been cited by other articles:

				A. G. Zabka, G. S. Mitchell, and M. Behan Conversion from testosterone to oestradiol is required to modulate respiratory long-term facilitation in male rats J. Physiol., November 1, 2006; 576(3): 903 - 912. [Abstract] [Full Text] [PDF]

				J. F. Reckelhoff, L. L. Yanes, R. Iliescu, L. A. Fortepiani, and J. P. Granger Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease Am J Physiol Renal Physiol, November 1, 2005; 289(5): F941 - F948. [Abstract] [Full Text] [PDF]

				T. K. Mandal Inhaled insulin for diabetes mellitus Am. J. Health Syst. Pharm., July 1, 2005; 62(13): 1359 - 1364. [Abstract] [Full Text] [PDF]